Ricerc@Sapienza

We read with great interest the study by Clementi et al.
that would like to explore the efcacy of a single intraarticular
injection of ultra-high molecular weight hyaluronic
acid in patients with hip osteoarthritis. Actually, we
believe that investigating just patients’ clinical status using
VAS and WOMAC scale should have been supported by
further information. In fact, in order to have more data that
could infuence the recent clinical practice, it is important to
consider also  the efect that the intra-articular injection of

OsteoArthritis (OA) is a theme currently representing an emerging topic for its increasing incidence. It is well known that it is a chronic disease that could lead to important long-lasting disability; this generates increasing costs for the health care system. OA treatment options vary: localization, aetiology, grading and symptomatology should be considered before choosing the most adequate therapy. Currently, a modern approach to managing OA involves SYmptomatic Slow Acting Drugs in Osteo-Arthritis (SYSADOAs).

Introduction: Osteoarthritis (OA) is the most common degenerative joint disease and it is mainly characterized by articular cartilage damage, synovial fibrosis and osteophyte formation. Osteophytes are osteo-cartilaginous outgrowths that involve the bone structure of osteoarthritic joints. In this study we analyzed how osteophytes evolution leads to a rearrangement of the stresses and strains within the subchondral trabecular bone.

Purpose: The KOOS questionnaire is used to assess the symptoms and function of patients with traumatic or degenerative knee pathology. The WOMAC score has been validated mainly in the context of knee osteoarthritis. The distribution of these scores in a non-diseased population is not known. The hypothesis was that KOOS and WOMAC scores were influenced by patients’ age, sex, and BMI. The primary objective of this study was to describe, for the first time, the distribution of KOOS and WOMAC scores in a healthy population based on age, sex, and BMI.

Selective cyclooxigenase (COX)-2 inhibitors were developed to prevent traditional non-steroidal anti-inflammatory drugs (tNSAIDs) gastro-intestinal adverse effects. VA692, a recently disclosed selective COX-2 inhibitor, structurally related to well-known marketed coxibs, showed anti-inflammatory, and anti-nociceptive properties. The aim of this study was to analyze the anti-inflammatory effect of VA692, in comparison with celecoxib.